Phase 2 Breast Cancer Trial, Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been diagnosed with triple negative breast cancer (a specific type of breast cancer that tests negative for three particular markers) confirmed by a laboratory test, at stage II or III at the time of diagnosis.
- People who are scheduled to receive or have received chemotherapy before surgery (called neoadjuvant chemotherapy), including as part of another clinical trial, following standard treatment guidelines.
- People whose blood test shows the presence of circulating tumour DNA (small fragments of cancer-related genetic material in the blood) at one of three specific timepoints: before chemotherapy, after chemotherapy, or after surgery.
- People with a general health and activity level rated as 0, 1, or 2 on a standard medical scale (meaning able to carry out daily activities with little to no limitation).
- People who agree in writing to provide blood and tumour samples for research purposes.
- People who are willing to have blood tests every 3 months and, if assigned to the treatment group, complete a 12-month course of a medicine called tislelizumab.
- People who have no signs of cancer that has spread to other parts of the body, based on scans taken at the time of diagnosis.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have previously taken part in other interventional clinical trials (confirm with trial site).
- People who have been diagnosed with another cancer within the 3 years before their breast cancer diagnosis.
- People who are pregnant or breastfeeding.
- People who have not provided written consent to participate.
- People who are unable to receive the standard chemotherapy before surgery, or radiotherapy afterwards if required.
- People who have an active autoimmune disease (a condition where the immune system mistakenly attacks the body's own tissues).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Qiang Liu, MD, Sunyat-sen Memorial Hospital
Phone: +86-15915939702
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
5 years Disease free survival(DFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.